Patents by Inventor Merrill Schaeffer

Merrill Schaeffer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150202282
    Abstract: The present invention comprises methods and compositions related to the production and use of amino acid sequences. In particular, PCV2 ORF2 is shown to be useful as a virus-like particle which produces amino acid sequences that retain their immunogenicity or antigenicity when the DNA encoding the PCV2 ORF2 is inserted into an expression system. DNA sequences that are foreign to PCV2 can be attached “in-frame” to the ORF2 DNA and the entire sequence, including the DNA foreign to PCV2, is expressed. It was shown that such sequences retain their antigenicity and therefore their potential utility in immunogenic compositions.
    Type: Application
    Filed: January 8, 2015
    Publication date: July 23, 2015
    Inventors: Eric Vaughn, Merrill Schaeffer
  • Publication number: 20150190497
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Application
    Filed: March 18, 2015
    Publication date: July 9, 2015
    Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
  • Patent number: 9011868
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: April 21, 2015
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
  • Publication number: 20130101621
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Application
    Filed: December 27, 2012
    Publication date: April 25, 2013
    Applicant: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
  • Publication number: 20110274710
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Application
    Filed: July 25, 2011
    Publication date: November 10, 2011
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
  • Patent number: 8025888
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: September 27, 2011
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
  • Publication number: 20110217327
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Application
    Filed: May 12, 2011
    Publication date: September 8, 2011
    Applicant: Boehringer Ingelheim Vetmedica, Inc
    Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
  • Patent number: 7968285
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: June 28, 2011
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
  • Patent number: 7910306
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: March 22, 2011
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
  • Publication number: 20110020394
    Abstract: The present invention comprises methods and compositions related to the production and use of amino acid sequences. In particular, PCV2 ORF2 is shown to be useful as a virus-like particle which produces amino acid sequences that retain their immunogenicity or antigenicity when the DNA encoding the PCV2 ORF2 is inserted into an expression system. DNA sequences that are foreign to PCV2 can be attached “in-frame” to the ORF2 DNA and the entire sequence, including the DNA foreign to PCV2, is expressed. It was shown that such sequences retain their antigenicity and therefore their potential utility in immunogenic compositions.
    Type: Application
    Filed: December 31, 2008
    Publication date: January 27, 2011
    Applicant: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Eric Vaughn, Merrill Schaeffer
  • Patent number: 7838213
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: November 23, 2010
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
  • Patent number: 7838214
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: November 23, 2010
    Assignee: Boehringer Ingelheim Vetmedical, Inc.
    Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
  • Patent number: 7833707
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from PCV2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: November 16, 2010
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
  • Patent number: 7829101
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: November 9, 2010
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
  • Patent number: 7829273
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: November 9, 2010
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
  • Patent number: 7700285
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Grant
    Filed: December 29, 2005
    Date of Patent: April 20, 2010
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
  • Publication number: 20090215698
    Abstract: The present invention provides nucleic acid and amino acid sequences useful as the immunogenic portion of vaccines or immunogenic compositions effective for lessening the severity of the clinical symptoms associated with Lawsonia intracellularis infection or conferring protective immunity to an animal susceptible to such infection. Preferred amino acid sequences include at least 9 contiguous amino acids from SEQ ID NOS 1 (IDFKAKGVWDFNNFE), 3 (IDFKAKGVWDFNNFEWQQSSFMKG), or 7 (MKLGYKISAGFAIGMIMVVLM). Thus, the nucleic acid sequences encoding such proteins, or the proteins themselves are included in vaccine compositions, together with veterinary-acceptable carrier and administered to an animal in need thereof.
    Type: Application
    Filed: April 18, 2006
    Publication date: August 27, 2009
    Applicant: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Merrill Schaeffer, Jeremy Kroll, Michael Roof
  • Publication number: 20090042245
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from PCV2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Application
    Filed: January 13, 2005
    Publication date: February 12, 2009
    Inventors: Mark Eichmeyer, Greg Nitzel, Merrill Schaeffer
  • Publication number: 20090022750
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Application
    Filed: June 12, 2008
    Publication date: January 22, 2009
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
  • Publication number: 20090022752
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Application
    Filed: June 12, 2008
    Publication date: January 22, 2009
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer